Free Trial

Genelux (GNLX) Competitors

Genelux logo
$3.34 -0.13 (-3.75%)
Closing price 04:00 PM Eastern
Extended Trading
$3.33 -0.01 (-0.30%)
As of 07:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GNLX vs. ATYR, SIGA, TRML, CGEM, MBX, RZLT, KMDA, TERN, RGNX, and SVRA

Should you be buying Genelux stock or one of its competitors? The main competitors of Genelux include aTyr Pharma (ATYR), Siga Technologies (SIGA), Tourmaline Bio (TRML), Cullinan Therapeutics (CGEM), MBX Biosciences (MBX), Rezolute (RZLT), Kamada (KMDA), Terns Pharmaceuticals (TERN), REGENXBIO (RGNX), and Savara (SVRA). These companies are all part of the "pharmaceutical products" industry.

Genelux vs. Its Competitors

Genelux (NASDAQ:GNLX) and aTyr Pharma (NASDAQ:ATYR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations, valuation and media sentiment.

aTyr Pharma's return on equity of -87.09% beat Genelux's return on equity.

Company Net Margins Return on Equity Return on Assets
GeneluxN/A -93.04% -74.17%
aTyr Pharma N/A -87.09%-64.77%

In the previous week, aTyr Pharma had 6 more articles in the media than Genelux. MarketBeat recorded 8 mentions for aTyr Pharma and 2 mentions for Genelux. Genelux's average media sentiment score of 0.94 beat aTyr Pharma's score of 0.59 indicating that Genelux is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Genelux
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
aTyr Pharma
2 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Genelux presently has a consensus target price of $17.75, indicating a potential upside of 431.44%. aTyr Pharma has a consensus target price of $20.20, indicating a potential upside of 246.48%. Given Genelux's stronger consensus rating and higher probable upside, equities analysts plainly believe Genelux is more favorable than aTyr Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genelux
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
3.20
aTyr Pharma
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
3.14

Genelux has higher earnings, but lower revenue than aTyr Pharma. aTyr Pharma is trading at a lower price-to-earnings ratio than Genelux, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genelux$10K12,611.84-$29.87M-$0.88-3.80
aTyr Pharma$230K2,255.96-$64.02M-$0.81-7.20

Genelux has a beta of -0.34, indicating that its stock price is 134% less volatile than the S&P 500. Comparatively, aTyr Pharma has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500.

37.3% of Genelux shares are owned by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are owned by institutional investors. 9.3% of Genelux shares are owned by company insiders. Comparatively, 3.7% of aTyr Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

aTyr Pharma beats Genelux on 8 of the 15 factors compared between the two stocks.

Get Genelux News Delivered to You Automatically

Sign up to receive the latest news and ratings for GNLX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GNLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GNLX vs. The Competition

MetricGeneluxMED IndustryMedical SectorNASDAQ Exchange
Market Cap$131.03M$3.07B$5.70B$9.51B
Dividend YieldN/A2.36%4.69%4.01%
P/E Ratio-3.8021.0428.0720.05
Price / Sales12,611.84284.46448.5799.42
Price / CashN/A42.7636.2258.56
Price / Book4.398.378.665.87
Net Income-$29.87M-$55.19M$3.25B$258.55M
7 Day Performance0.30%5.89%4.20%2.23%
1 Month Performance13.61%17.63%10.82%12.76%
1 Year Performance73.96%5.09%34.70%19.36%

Genelux Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GNLX
Genelux
1.2316 of 5 stars
$3.34
-3.7%
$17.75
+431.4%
+59.9%$131.03M$10K-3.8010Positive News
Analyst Forecast
Gap Up
ATYR
aTyr Pharma
2.1682 of 5 stars
$5.53
+4.3%
$20.20
+265.3%
+187.6%$492.17M$230K-6.8353Gap Up
High Trading Volume
SIGA
Siga Technologies
1.9892 of 5 stars
$6.86
+1.3%
N/A-27.4%$490.08M$138.72M10.2440News Coverage
Upcoming Earnings
Options Volume
TRML
Tourmaline Bio
1.9085 of 5 stars
$18.96
+5.5%
$49.33
+160.2%
+13.8%$486.99MN/A-5.9144News Coverage
Positive News
CGEM
Cullinan Therapeutics
2.0273 of 5 stars
$7.87
+2.2%
$30.00
+281.2%
-59.0%$464.41MN/A-2.7030Positive News
MBX
MBX Biosciences
2.1326 of 5 stars
$13.87
+6.4%
$37.50
+170.4%
N/A$463.59MN/A0.0036News Coverage
RZLT
Rezolute
2.5489 of 5 stars
$5.32
+1.1%
$11.83
+122.4%
+26.5%$454.97MN/A-4.6340News Coverage
Analyst Revision
KMDA
Kamada
4.1156 of 5 stars
$7.78
+0.4%
$13.00
+67.1%
+33.7%$447.39M$167.24M26.83360News Coverage
Positive News
TERN
Terns Pharmaceuticals
3.9741 of 5 stars
$5.11
+4.3%
$15.63
+205.8%
-30.1%$446.31MN/A-4.6940
RGNX
REGENXBIO
4.1758 of 5 stars
$8.70
+0.2%
$31.63
+263.5%
-33.1%$436.39M$83.33M-2.80370News Coverage
Positive News
SVRA
Savara
1.8468 of 5 stars
$2.51
+5.0%
$5.60
+123.1%
-43.5%$433.83MN/A-5.2320Positive News

Related Companies and Tools


This page (NASDAQ:GNLX) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners